BBK Worldwide^® Blog

Meaningful Engagement at Critical Touchpoints along the Patient Journey

There's no better way to illustrate the importance of meaningful engagement than with the story of one family's journey from clinical trial awareness to participation. The story shows how the right mix of digital and physical touchpoints plays a critical role in creating a positive patient experience. The family's journey begins below.

New eBook Available for Download

As we continue to focus our attention on underserved populations, we've just released a content-rich eBook full of guidance that study sponsors can leverage to create a more diverse and inclusive clinical trial environment. It features a bonus section with excerpts from our recent Q&A with Michele Russell-Einhorn, chief compliance officer and institutional official at Advarra, that provide an IRB's perspective on improving diversity and inclusion in clinical trials.

Earlier this week, BBK Principal Rob Laurens went one-on-one with Outsourcing-Pharma discussing the launch of BBK's Engagement Solution Center for decentralized and post-marketing clinical trials, which features concierge service delivery and a robust patient experience portal to ease the clinical trial journey.

In this in-depth interview, Rob addresses the importance and advantages of centralizing design, management, operations, and communications of patient support services. In addition, he provides insight into some of the conversations that led to the creation of the center. Click here to read the full article.

BBK Worldwide® Launches the Engagement Solution Center for Decentralized and Post-Marketing Clinical Trial Success

Concierge Service Delivery and Robust Patient Experience Portal Ease Clinical Trial Journey

The COVID-19 pandemic has significantly accelerated the need to reshape research and development. Most specifically, it has led to demand for increased funding for decentralized and larger randomized clinical trials to inform clinical decisions and guide future research.

By launching the Engagement Solution Center, BBK Worldwide® (BBK) is making patient-centric and inclusive trials an immediate and actionable reality for study sponsors.

Improving Diversity and Inclusion in Clinical Trials

One-on-One with Advarra

Get an IRB's perspective on improving diversity and inclusion in clinical trials by watching our interview with Michele Russell-Einhorn, Chief Compliance Officer and Institutional Official at Advarra.

3 Decentralized Clinical Trial Solutions Trending Now

Ever wonder which products and services study sponsors are leveraging for enrollment and engagement success? We thought we would take a moment to share the products and services gaining traction with our clients who are embracing decentralized clinical trials. And while it's always important to keep in mind that each study protocol is unique and requires its own analysis to determine the right solutions, we're sharing three popular ones below.

PHARMA15 LIVE!

How Do Patients Feel About Hybrid
and Decentralized Clinical Trials?

What Are Must-Haves for
a Positive Patient Experience?

Patient advocates take center stage in this Pharma15 Live! overtime segment and share their thoughts on hybrid and decentralized clinical trials.

Moderated by BBK Worldwide^® Founding Principal Bonnie A. Brescia, this segment continues the conversation from a Patients as Partners Europe panel and answers questions asked by study sponsors in attendance.

Strategies to Help Improve Clinical Trial Diversity and Inclusion

From Engaging Locally to Removing Financial Obstacles

With health equity at the forefront of many conversations today, study sponsors are seeking ways to make clinical trial participation more inclusive.

At BBK Worldwide, we believe that clinical trials for investigational treatments should reflect the populations that could benefit from them, with the long-term goal of achieving better health interventions for those in greatest need. To help facilitate participation of underserved populations, we have outlined strategic guidance that study sponsors can leverage in their efforts.

We recently sat down with BBK’s Global Strategist Amanda Moody to discuss the company’s commitment to Parkinson’s disease clinical research, including ongoing innovation designed to foster a positive and meaningful patient journey. 

Can you briefly describe BBK’s experience with the Parkinson’s disease community?

We have a long-standing commitment to the Parkinson’s community, both in terms of supporting clinical research as well as individual patient and caregiver needs. 

Sharing in the commitment to advance research and knowledge for the Parkinson’s disease community, BBK Worldwide is proud to support the 2021 Parkinson’s Disease Therapeutics Webinar Series, hosted by The Michael J. Fox Foundation.

This free online series brings together Parkinson’s researchers, drug developers, and clinicians to discuss new findings and trending topics in Parkinson’s research and development.